ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN- COST-UTILITY ANALYSIS
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1211
https://www.valueinhealthjournal.com/article/S1098-3015(15)03287-8/fulltext
Title :
ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN- COST-UTILITY ANALYSIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03287-8&doi=10.1016/j.jval.2015.09.1211
First page :
A464
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
709